Skip to main content
Canna~Fangled Abstracts

Dos(e)Age: Role of Dose and Age in the Long-Term Effect of Cannabinoids on Cognition

By February 19, 2022February 28th, 2022No Comments
Review

doi: 10.3390/molecules27041411.

Affiliations 
  • PMID: 35209200

Free PMC article

Abstract

Cannabis is still the most widely used illicit drug around the world. While its use has always been prevalent among adolescents, recent evidence suggests that its consumption is also increasing among other population groups, such as pregnant women and aged people. Given the known impact of cannabis on brain development and behavior, it is important to dissect the possible long-term impact of its use across different age groups, especially on measures of cognitive performance. Animal models of cannabinoid exposure have represented a fundamental tool to characterize the long-lasting consequences of cannabinoids on cognitive performance and helped to identify possible factors that could modulate cannabinoids effects in the long term, such as the age of exposure and doses administered. This scoping review was systematically conducted using PubMed and includes papers published from 2015 to December 2021 that examined the effects of cannabinoids, either natural or synthetic, on cognitive performance in animal models where exposure occurred in the prenatal period, during adolescence, or in older animals. Overall, available data clearly point to a crucial role of age in determining the long-term effect of cannabinoid on cognition, highlighting possible detrimental consequences during brain development (prenatal and adolescent exposure) and beneficial outcomes in old age. In contrast, despite the recent advances in the field, it appears difficult to clearly establish a possible role of dosage in the effects of cannabinoids on cognition, especially when the adolescent period is taken into account.

Keywords: adolescence, aging, animal studies, cannabinoids, cognition, prenatal period

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1

References

    1. United Nations . World Drug Report 2021. United Nations Publication; New York, NY, USA: [(accessed on 29 December 2021)]. Sales No. E.21.XI. Available online: https://www.unodc.org/unodc/en/data-and-analysis/wdr2021.html.
    1. Di Forti M., Quattrone D., Freeman T.P., Tripoli G., Gayer-Anderson C., Quigley H., Rodriguez V., Jongsma H.E., Ferraro L., La Cascia C., et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): A multicentre case-control study. Lancet Psychiatry. 2019;6:427–436. doi: 10.1016/S2215-0366(19)30048-3. – DOI – PMC – PubMed
    1. European Monitoring Centre for Drugs and Drug Addiction . European Drug Report 2020: Key Issues Summary. Publications Office of the European Union; Luxembourg: 2020. [(accessed on 29 December 2021)]. Available online: https://www.emcdda.europa.eu/publications/edr/key-issues/2020_en.
    1. U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality National Survey on Drug Use and Health 2016 (NSDUH-2016-DS0001) [(accessed on 29 December 2021)];2018 Available online: https://www.datafiles.samhsa.gov/dataset/national-survey-drug-use-and-he….
    1. Han B.H., Palamar J.J. Trends in Cannabis Use Among Older Adults in the United States, 2015–2018. JAMA Intern. Med. 2020;180:609–611. doi: 10.1001/jamainternmed.2019.7517. – DOI – PMC – PubMed

Publication types

LinkOut – more resources


Leave a Reply